All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On September 23, 2024, the U.S Food and Drug Administration (FDA) approved bimekizumab, an interleukin (IL)-17 inhibitor that dually inhibits IL-17A and IL-17F, for the treatment of active psoriatic arthritis (PsA) in adults, in addition to active non-radiographic axial spondylarthritis and active ankylosing spondylarthritis.1 Bimekizumab was previously approved for the treatment of moderate-to-severe plaque psoriasis.1
The approval in PsA follows positive results from the phase III multicenter, randomized, placebo-controlled BE OPTIMAL and BE COMPLETE trials, which met the primary endpoint of 50% improvement in American College of Rheumatology response (ACR50) at Week 16.1 Responses were sustained to Week 52 in these trials and the open-label extension.1
This expanded indication makes bimekizumab a promising treatment option in patients with psoriasis at risk of PsA or in those with concurrent PsA.
Your opinion matters
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox